A transplant using the patient's own stem cells (an autologous stem cell transplant) or CAR T-cell therapy are treatment options for patients with certain types of lymphoma.

Multiple myeloma is a cancer of plasma cells, which are blood cells that are responsible for producing antibodies to fight infections. Patients with multiple myeloma often undergo a stem cell transplant as part of their initial treatment. Maintenance therapy after a stem cell transplant can enable myeloma patients to live longer but can also cause side effects.

Acute myeloid leukemia is a fast-moving cancer that can be fatal in weeks or months without treatment. This presentation reviews the causes, symptoms, and treatments for AML and recent progress in cure rates or prolonged remission for an increasing number of patients.

Myelodysplastic syndrome (MDS) is a blood disorder that can develop into leukemia. There are several treatments for MDS, including stem cell transplantation. This presentation reviews key features of MDS, treatment options and when a transplant is an appropriate remedy.

Acute myeloid leukemia (AML) is a blood cancer that has been historically challenging to treat. It often requires a bone marrow or stem cell transplant that can be curative but brings significant risks and side effects. However, new drugs and clinical trials have expanded treatment options and moderated side effects for many patients.

Sickle cell disease disproportionately affects African Americans. However, stem cell transplants and gene therapy offer promising treatment options. This presentation describes these treatments, their outcomes, and which treatments are appropriate for which patients.

Stem cell transplants can be a successful treatment option for older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Patients with high-risk AML or MDS who undergo a transplant fare better than high-risk patients who do not have a transplant.

Multiple myeloma is the most common cancer of the bone marrow. This presentation discusses transplant options and drug therapies for treating myeloma. It also reviews options for maintenance therapy and responding to relapses.

The current standard of care for patients with multiple myeloma is high dose chemotherapy and an autologous stem cell transplant. Although an autologous transplant is not a cure, maintenance therapy with various drugs can control myeloma in many patients for several years.

A stem cell transplant is a treatment option for some lymphoma patients who are at risk of relapsing after standard chemotherapy. CAR-T therapy is a new type of immunotherapy that is available to patients with B-cell lymphoma who relapsed or did not obtain a remission after standard chemotherapy.